16 September 2026 editorial review · Item
CamAPS FX: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Thriving evidence review — 16 September 2026
Record: CamAPS FX
Scope and findings:
- AddedLibertywithrestrictedindication andcountryrollout. Keptstandardhybridoutcomes/scoringseparate. CamAPSFXcorrectedlongstandingfalse noFDAclearance claim.
- Substantive software support review: August 31 Android version retirement and September notices. Country and pump variants distinguished; clinical performance and global supply not revalidated by this check.
Primary sources checked:
Limits: The review is restricted to the scopes above. Historical efficacy estimates, editorial scoring and country-specific access were not fully reverified unless expressly stated. A manufacturer or conference report retains that evidence level.
Thriving evidence review — 16 September 2026
Additional second-pass scope: AiDAPT10.5pp explicitly adjusted, not raw subtraction. Boost/Ease-off paper supports observed lower TAR but user-selected retrospective modes do not prove causality; retained accurately attributed no-SHE/DKA statement.
Primary sources checked:
Limits: Only the specific claims and scoring interpretation above were revisited. This does not revalidate every historical outcome or regional access claim.